# Ancheng Capital

> Ancheng Capital is a VC fund backing Biotechnology, Genetics and Biopharma. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: May 2026
- Lead investor: 0%
- Last updated: Aug 2026

Ancheng Capital is a VC fund focused on Biotechnology and Genetics. Ancheng Capital

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Genetics | 1 | 33% |
| Biopharma | 1 | 33% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 2 | 67% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Interstellar Development | Interstellar Development is a commercial spacecraft research and development company focused on the design, engineering, and advancement of innovative space technologies, aiming to deliver reliable, cost-effective solutions for next-generation launch vehicles, satellites, and space exploration missions. |  | Series A | May 21, 2026 |  |
| Kind Pharmaceutical | Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs. The company was founded in 2013 and is headquartered in Redwood City, California, United States. | $50M | Series B | Dec 27, 2021 |  |
| General Biosystems | General Biosystems is a biotechnology company that focuses on high-quality, high-throughput, automated production of DNA constructs. The company through its passion in understanding how genetic information is stored and programmed in the DNA develops innovative technologies and instruments to program and physically write or print new genetic codes.The new codes will create blueprints for new or enhanced biological and biological functions. |  | Venture - Series Unknown | May 17, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Gaorong Capital](https://shizune.co/investors/profile/banyan-capital) — VC Fund, 1 deal together
- [Chengdu High-tech Ceyuan Capital](https://shizune.co/investors/profile/chengdu-high-tech-ceyuan-capital) — VC Fund, 1 deal together
- [Chengdu Science and Technology Venture Capital](https://shizune.co/investors/profile/chengdu-science-and-technology-venture-capital-group) — VC Fund, 1 deal together
- [Decheng Capital](https://shizune.co/investors/profile/decheng-capital) — VC Fund, 1 deal together
- [EFung Capital](https://shizune.co/investors/profile/efung-capital) — VC Fund, 1 deal together
- Jinduo Investment — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ancheng Capital invest in?

Ancheng Capital invests primarily in Biotechnology, Genetics and Biopharma startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ancheng Capital last invest?

The most recent investment recorded for Ancheng Capital closed in May 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co